Heartflow (NASDAQ:HTFL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Heartflow (NASDAQ:HTFL) from a hold rating to a buy rating in a report released on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on the company. Canaccord Genuity Group raised their price objective on Heartflow from $45.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. UBS Group began coverage on shares of Heartflow in a research report on Wednesday, September 9th. They set a “neutral” rating and a $55.00 price target on the stock. Wells Fargo & Company lifted their price target on shares of Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Stifel Nicolaus upped their price objective on shares of Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.25.

Heartflow Stock Performance

Shares of NASDAQ:HTFL opened at $52.21 on Friday. The firm has a market capitalization of $4.54 billion, a PE ratio of -28.53 and a beta of 2.73. Heartflow has a 52-week low of $20.13 and a 52-week high of $53.07. The firm has a fifty day moving average of $43.10 and a 200 day moving average of $33.85.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The business had revenue of $64.08 million for the quarter. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. On average, sell-side analysts forecast that Heartflow will post -0.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other Heartflow news, CFO Vikram Verghese sold 29,714 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $50.06, for a total value of $1,487,482.84. Following the completion of the sale, the chief financial officer owned 184,789 shares in the company, valued at approximately $9,250,537.34. The trade was a 13.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 19,682 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $50.15, for a total value of $987,052.30. Following the sale, the insider directly owned 79,956 shares of the company’s stock, valued at approximately $4,009,793.40. This trade represents a 19.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 287,767 shares of company stock valued at $12,871,623 in the last ninety days. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Heartflow

Large investors have recently added to or reduced their stakes in the company. XXEC Inc. bought a new position in shares of Heartflow during the second quarter valued at about $2,524,764,000. BlackRock Inc. bought a new stake in shares of Heartflow in the second quarter worth about $152,502,000. Bamco Inc. NY purchased a new position in Heartflow during the 2nd quarter valued at about $94,625,000. Jupiter Topco LLC bought a new position in Heartflow during the 2nd quarter valued at approximately $70,983,000. Finally, Janus Henderson Group PLC lifted its holdings in Heartflow by 152.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after buying an additional 1,315,416 shares during the period.

Heartflow Company Profile

HeartFlow, Inc is a medical technology company focused on improving the diagnosis and management of coronary artery disease. The company develops software and clinical tools that use artificial intelligence, advanced image analysis and data from coronary computed tomography angiography (CCTA) scans to provide noninvasive assessments of blood flow and potential blockages in the heart.

Its principal product is the HeartFlow Analysis, which creates a personalized, three-dimensional model of a patient’s coronary arteries and can estimate the impact of blockages on blood flow.